Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01142726 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 511
- Enrollment target
NCT01142726 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 511 participants.
The verdict
NCT01142726, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 511 participants
- Enrollment target
Study Summary
The primary purpose of the protocol is to demonstrate the ability of abatacept plus methotrexate to induce remission in patients with very early rheumatoid arthritis after 12 months of treatment and to maintain remission following 6 months of drug withdrawal.
Interventions
- DRUG Abatacept
- DRUG Methotrexate
- DRUG Methotrexate placebo
- DRUG Abatacept placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 511 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01142726
The ClinicalTrials.gov registry entry for NCT01142726 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 511 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Abatacept is the first listed.
NCT01142726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01142726 about?
NCT01142726 is a clinical study titled "Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis". The primary purpose of the protocol is to demonstrate the ability of abatacept plus methotrexate to induce remission in patients with very early rheumatoid arthritis after 12 months of treatment and to maintain remission following 6 months of drug withdrawal.
What is the current status of trial NCT01142726?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 511 participants. The study started on 2010-12. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01142726?
The interventions under investigation include: Abatacept (DRUG), Methotrexate (DRUG), Methotrexate placebo (DRUG), Abatacept placebo (DRUG).
Who is sponsoring clinical trial NCT01142726?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.